WO2013094988A1 - Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same - Google Patents
Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same Download PDFInfo
- Publication number
- WO2013094988A1 WO2013094988A1 PCT/KR2012/011114 KR2012011114W WO2013094988A1 WO 2013094988 A1 WO2013094988 A1 WO 2013094988A1 KR 2012011114 W KR2012011114 W KR 2012011114W WO 2013094988 A1 WO2013094988 A1 WO 2013094988A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- cancer
- culture
- cytokine
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 238
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- 208000035473 Communicable disease Diseases 0.000 title claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims abstract description 278
- 238000000034 method Methods 0.000 claims abstract description 42
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 102000004127 Cytokines Human genes 0.000 claims description 43
- 108090000695 Cytokines Proteins 0.000 claims description 43
- 238000004114 suspension culture Methods 0.000 claims description 20
- 102000009027 Albumins Human genes 0.000 claims description 17
- 108010088751 Albumins Proteins 0.000 claims description 17
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 15
- 108010002350 Interleukin-2 Proteins 0.000 claims description 14
- 102000000588 Interleukin-2 Human genes 0.000 claims description 14
- 210000005259 peripheral blood Anatomy 0.000 claims description 13
- 239000011886 peripheral blood Substances 0.000 claims description 13
- 210000000265 leukocyte Anatomy 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 238000004113 cell culture Methods 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 206010029260 Neuroblastoma Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 102000003812 Interleukin-15 Human genes 0.000 claims description 7
- 108090000172 Interleukin-15 Proteins 0.000 claims description 7
- 102100030704 Interleukin-21 Human genes 0.000 claims description 5
- 108010074108 interleukin-21 Proteins 0.000 claims description 5
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- 108010065805 Interleukin-12 Proteins 0.000 claims description 4
- 102000013462 Interleukin-12 Human genes 0.000 claims description 4
- 102000003810 Interleukin-18 Human genes 0.000 claims description 4
- 108090000171 Interleukin-18 Proteins 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 229940117681 interleukin-12 Drugs 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 2
- 208000005176 Hepatitis C Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 229940127174 UCHT1 Drugs 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 230000003013 cytotoxicity Effects 0.000 abstract description 53
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 53
- 230000003833 cell viability Effects 0.000 abstract description 28
- 230000008014 freezing Effects 0.000 abstract description 16
- 238000007710 freezing Methods 0.000 abstract description 16
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 5
- 238000012136 culture method Methods 0.000 abstract description 4
- 208000012868 Overgrowth Diseases 0.000 abstract description 2
- 230000001771 impaired effect Effects 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 description 40
- 239000002609 medium Substances 0.000 description 34
- 230000000638 stimulation Effects 0.000 description 30
- 230000001093 anti-cancer Effects 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 23
- 238000010171 animal model Methods 0.000 description 21
- 230000035755 proliferation Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical class P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 230000028327 secretion Effects 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000010257 thawing Methods 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000012979 RPMI medium Substances 0.000 description 6
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002659 cell therapy Methods 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 208000005017 glioblastoma Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940047122 interleukins Drugs 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 229960004964 temozolomide Drugs 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 2
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 101150069255 KLRC1 gene Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000013413 tumor xenograft mouse model Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0278—Physical preservation processes
- A01N1/0284—Temperature processes, i.e. using a designated change in temperature over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1157—Monocytes, macrophages
Definitions
- the present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells“), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same.
- NK cells“ natural killer cells
- Immune cells that directly remove cancer cells include NK cells and cytotoxic T lymphocytes (CTLs), and that present antigens to these effector cells include dendritic cells (DCs) or B cells.
- CTLs cytotoxic T lymphocytes
- DCs dendritic cells
- Other examples include helper T cells (Th cells), regulatory T cells (Treg cells) and the like, which secrete various cytokines.
- Th cells helper T cells
- Treg cells regulatory T cells
- NK cells are recognized as the most rapidly effective and efficient immune cells.
- NK cells are lymphocytes that account for about 10% of blood cells and play an important role in immune responses. NK cells have various functions, and particularly have the ability to kill cancer cells or cells infected with external pathogenic bacteria, and thus function to remove cancer cells, or cells developing into cancers.
- NK cells are normally present in the body in an inactivated state, but in order to use NK cells for therapeutic purposes, NK cells need to be activated. Thus, studies on the activation of NK cells from normal blood or the inactivated blood of patients have been actively conducted.
- NK cells activated ex vivo have the rapeutic effects on various cancers, particularly blood cancer such as leukemia, when they are administered after allogenic bone marrow transplantation ( Blood Cells Molecules & Disease , 33: p261-266, 2004).
- blood cancer such as leukemia
- NK cells activated ex vivo have the rapeutic effects on various cancers, particularly blood cancer such as leukemia, when they are administered after allogenic bone marrow transplantation ( Blood Cells Molecules & Disease , 33: p261-266, 2004).
- the distinct therapeutic effects of NK cells on solid cancers other than blood cancer have not yet been clinically proven. Specifically, it was reported that the administration of NK cells before the formation of cancers can interfere with the engraftment of cancers ( Cancer Immunol.
- NK cells are not sufficiently cultured and expanded in vitro .
- a technology for culturing and expanding NK cells at useful levels has received attention, and many studies thereon have been conducted, but the study results are still not clinically applicable.
- NK cells were expanded using cancer cell lines as feeder cells. It was reported that the use of the leukemia cell line CTV-1 showed little or no improvement in proliferation ( J. Immunol ., 178(1):p85-94,2007) and that culture using EBV-LCL for 21 days increased the cell number by an average of about 490 folds ( Cytotherapy , 11(3): p341-355, 2009).
- NK cells for 3 weeks using artificial APC obtained by expressing 4-1BBL and membrane-bound IL-15 in the K562 cells increased the NK cell number by an average of 227 folds, and high cytotoxicity appeared in vitro and in vivo , but limited proliferation caused by cell death was shown ( Cancer Res ., 69(9): p4010-4017, 2009).
- NK cells obtained by enrichment of NK cells from peripheral blood leukocytes (PBLs) without the isolation of NK cells have low cytotoxicity compared to pure NK cells, and contain T-cells that recognize self and non-self cells by autologous MHC molecules. Thus, the cells are limited to autologous transplantation, as long as T-cells are not removed.
- a method comprising NK cells isolation step, and expanding the isolated NK cells with suitable stimulation using feeder cells, and a method of selectively expanding NK cells using whole PBL or peripheral blood mononuclear cells (PBMCs).
- PBMCs peripheral blood mononuclear cells
- irradiated feeder cells such as PBMCs [Cytotherapy 12: 750-763, 2010], Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCLs) [Cytotherapy 11: 341-55, 2009] are often used. Irradiated feeder cells stimulate NK cells through both humoral factors and direct cell-to-cell contact [Blood 80: 2221-2229, 1992].
- NK cells we established a simplified and efficient method for the large-scale expansion and activation of NK cells from healthy volunteers for clinical use.
- the depleted PBMCs were stimulated and expanded with irradiated autologous PBMCs repeatedly in the presence of OKT3 and IL-2, resulting in a highly pure population of CD3-CD16+CD56+ NK cells which is desired for allogeneic purpose.
- albumin is one of proteins constituting the basic substance of cell and has the lowest molecular weight among simple proteins present in nature.
- Albumin is generally known to be used as a preservative for biological formulations, but the use of albumin to increase the stability of NK cells has not yet been reported.
- Another object of the present invention is to provide a composition containing NK cells having improved long-term storage stability and a pharmaceutical formulation comprising the same.
- the composition according to the present invention may be provided as a frozen product and maintain high cell viability and cytotoxicity of the NK cells even when it is thawed.
- NK cells produced according to the method of the present invention and a composition comprising the same can be effectively used for treatment of cancers and infectious diseases.
- FIG. 1 shows the change in proliferation of NK cells by re-stimulation with feeder cells.
- (a) shows the change in proliferation rate of NK cells according to the number of re-stimulations. (a), once: application of stimulation once at day 0; twice: application of stimulation twice at days 0 and 7; and three times: application of stimulation three times at days 0, 7 and 14.
- (b) shows the change in proliferation rate of NK cells according to the time point of application of re-stimulation, wherein D0: application of stimulation once at day 0; D0/D7: application of stimulation twice at days 0 and 7; and D0/D10: application of stimulation twice at days 0 and 10.
- FIG. 2 shows a change in the cell viability of NK cells cultured by re-stimulation with feeder cells, wherein D0: application of stimulation once at day 0; D0/D7: application of stimulation twice at days 0 and 7; and D0/D10: application of stimulation twice at days 0 and 10.
- FIG. 3 shows a change in the cytotoxicity of NK cells cultured by re-stimulation with feeder cells, wherein D0: application of stimulation once at day 0; D0/D7: application of stimulation twice at days 0 and 7; and D0/D10: application of stimulation twice at days 0 and 10.
- FIG. 4 shows analysis results for the phenotype of NK cells cultured by re-stimulation with feeder cells, wherein (a1 & a2): identity and purity of NK cells; (b1 & b2): activating receptors of NK cells; and (c1 & c2): inhibitory receptors of NK cells.
- FIG. 5 shows the changes in cell viability and cytotoxicity according to the concentration of albumin in a composition containing NK cells, wherein (a) change in the viability of NK cells; and (b) change in the cytotoxicity of NK cells.
- FIG. 6 shows the changes in cell viability, cytotoxicity and phenotype of NK cells in a composition, which result from the addition of albumin, wherein (a) change in the viability of NK cells; (b) change in the cytotoxicity of NK cells; and (c) change in the phenotype of NK cells.
- FIG. 7 shows the change in NK cells resulting from freezing, wherein (a) cell viability after freezing/thawing; (b) recovery after freezing/thawing; (c) cytotoxicity after freezing/thawing; and (d): expression level of cell phenotypes on CD56+ cells after freezing/thawing.
- FIG. 8 shows the anticancer effect of NK cells in a lymphoma animal model, wherein (a) the effect on the alleviation of hind leg paralysis in test model; and (b) the effect on improvement in the survival of test model.
- FIG. 9 shows the anticancer effect of NK cells in a brain cancer (glioblastoma) animal model upon intracranial administration, wherein (a) the results of observing the tumor volume by histological examination; (b) the results of TUNEL analysis according to the cell number; and (c) the change in tumor volume according to the number of NK cells.
- FIG. 10 shows the anticancer effect of NK cells in a brain cancer animal model upon intravenous administration, wherein (a): the results of observing tumor volume by histological examination; and (b) the change in tumor volume according to the number of NK cells.
- FIG. 11 shows the anticancer effect of NK cells in a brain cancer animal model when administered in combination with an anticancer agent.
- FIG. 12 shows the anticancer effect of NK cells in an ovarian cancer animal model, wherein (a) the change of tumor size as a function of the administration period of NK cells (in vivo images); and (b) the results of observing the change in tumor size resulting from NK cell administration.
- FIG. 13 shows the anticancer effect of NK cells in a liver cancer animal model.
- FIG. 14 shows the anticancer effect of NK cells in a neuroblastoma animal model.
- FIG. 15 shows the in-vitro efficacy of NK cells against various cancer cell lines and virus infected cell lines.
- a method for producing NK cells according to the present invention comprises;
- T cell-depleted mononuclear cells with anti-CD3 antibody and feeder cells in a cytokine-containing medium, and carrying out stationary culture for several days to stimulate cell-cell contact, carrying out stationary or suspension culture of NK cells in a reactor while maintaining the cell concentration and the cytokine concentration at constant levels.
- NK cells produced by the method of the present invention maintain high cell viability and cytotoxicity to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration.
- stationary culture following initial stimulation is performed for about 2-15 days, preferably 5-10 days, and stationary culture following re-stimulation is performed for about 2-7 days, preferably 3-5 days.
- the cells are preferably stationary or suspension-cultured in an incubator while the concentration of cytokine is maintained at a constant level.
- the method for producing NK cells according to the present invention may, for example, comprise the steps of:
- step (iii) after completion of stationary culture in step (ii), re-stimulating the cells by addition of cytokine, anti-CD3 antibody and feeder cells, and carrying out stationary culture for 2-7 days, preferably 3-5 days, to stimulate cell-cell contact;
- step (iii) of re-stimulating the cells and carrying out stationary culture may be repeated once or more.
- the method of the present invention may further comprise, before step (ii), a step of preparing feeder cells.
- the term “stationary culture“ means culturing cells in an incubator in a stationary state without agitation or shaking
- the term “suspension culture“ means culturing cells in a suspended state by aeration or agitation without attaching the cells to the bottom or side of the reactor.
- Examples of a reactor which can be used for stationary culture in the present invention include, but are not limited to, flasks, T-flasks, disposable cell culture bags and the like.
- Examples of a reactor which can be used for suspension culture in the present invention include, but are not limited to, shaking flasks, shaking incubators, fermentors, T-flasks, disposable cell culture bags and the like.
- any bioreactor may be used which is suitable for achieving the object of the present invention and can be easily selected by a person skilled in the art to which the present invention pertains.
- the reactor for stationary culture and suspension culture may be the same or different.
- stationary culture is completed and then a medium containing necessary nutrient components such as cytokine may additionally be supplied to the same reactor, followed by suspension culture.
- a medium containing necessary nutrient components such as cytokine may additionally be supplied to the same reactor, followed by suspension culture.
- the cultured cells may be transferred into the reactor for suspension culture.
- reactor for suspension culture examples include, but are not limited to, a wave bioreactor (GE Healthcare), a single-use bioreactor (SUB; Thermo Fisher), a single-use XDR bioreactor (Xcellerex), a cell culture bag (Nipro), a PBS series cell incubator (PBS Biotech) (see WO 07/111677A, WO 08/133845A, and WO 09/132192A), a cell culture bag (Fujimori), a disposable shake flasks (Erlenmeyer) and so on. Particularly, a PBS series cell incubator (PBS Biotech) is preferred.
- feeder cells refers to cells which do not have the ability to divide and proliferate, but have metabolic activity, and thus produce various metabolic products assisting in the proliferation of target NK cells.
- feeder cells include, but are not limited to, animal cell lines introduced with genes, peripheral blood leukocytes (PBL) treated with various cytokines or compounds, autologous or allogeneic peripheral blood leukocytes (PBL), T-cells, B-cells, monocytes and the like.
- PBL peripheral blood leukocytes
- PBL peripheral blood leukocytes
- PBL peripheral blood leukocytes
- PBL autologous or allogeneic peripheral blood leukocytes
- T-cells T-cells
- B-cells B-cells
- monocytes monocytes
- other feeder cells known in the art may be used as long as they coincide with the object of the present invention.
- the autologous peripheral blood monocytes that are used as feeder cells may be used in an inactivated state in order to ensure safety.
- inactivation a conventional method known in the art may be used.
- irradiation with gamma-rays may be used.
- the inactivated feeder cells include isolated T-cells.
- the method that uses feeder cells as described in the present invention is a method of expanding NK cells after isolation and is advantageous in that only pure NK cells continuously proliferate.
- Anti-CD3 antibody“ in the present invention is an antibody that binds specifically to a CD3 antigen, a molecule binding specifically to a T cell receptor (TCR) to form an antibody recognition complex, in which the CD3 molecule binds to TCR to transfer an antigen recognition signal into a cell.
- TCR T cell receptor
- any antibody may be used without limitation in the present invention, as long as it has the property of binding to CD3.
- the anti-CD3 antibody is preferably selected from the group consisting of OKT3, UCHT1, and HIT3a, but is not limited thereto.
- cytokine that may be included in the medium is preferably one or more selected from among interleukins.
- interleukins collectively refers to biologically active proteins which are produced by immune cells such as lymphocytes, monocytes or macrophages.
- An interleukin that may be used in the present invention is one or more selected from the group consisting of interleukin-2 (IL-2), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18) and interleukin-21 (IL-21).
- IL-2 interleukin-2
- IL-12 interleukin-12
- IL-15 interleukin-15
- IL-18 interleukin-18
- IL-21 interleukin-21
- IL-2 is preferably used, but is not limited.
- other cytokines known to those skilled in the art may also be used without limitation, as long as they coincide with the object of the present invention.
- the anti-CD3 antibody is used for stationary culture and suspension culture, and the concentration of anti-CD3 antibody in medium is 0.1-1,000 ng/ml, preferably 1-100 ng/ml, and more preferably 5-20 ng/ml, and the concentration of cytokine in medium is 10-2,000 IU, preferably 100-1,000 IU, and more preferably about 200-700 IU.
- stimulation means inducing the proliferation of NK cells by adding feeder cells or the like thereto, and anti-CD3 antibody together with feeder cells may also be used for stimulation.
- re-stimulation means re-inducing the proliferation of NK cells again by adding feeder cells and/or anti-CD3 antibody thereto after a certain time of culture.
- a medium for use in the production of NK cells may be a conventional medium for animal cell culture, such as CellGro medium (Cellgenix), AIM-V medium, RIMI-1640 medium or X-VIVO20 medium.
- This medium for animal cell culture may, if necessary, contain one or more components selected from among NK cells isolated from human peripheral blood, peripheral blood monocytes, anti-CD3 antibodies and interleukins.
- the concentrations of cytokine and cells in a medium can be measured at regular intervals of time, and based on the measurements, cytokine-containing medium may be provided according to the cell concentration and the cytokine concentration.
- the medium for culture may contain serum, plasma or an additional proliferation factor that supports the proliferation of lymphocytes.
- Serum or plasma that is added to the medium is not specifically limited and may be a commercial product derived from an animal. More preferably, human autologous serum or plasma is used.
- cytokines that induce the proliferation of lymphocytes from peripheral blood monocytes or lectins stimulates the proliferation of lymphocytes.
- NK cells produced according to the method of the present invention may be provided as a therapeutic composition using a suitable excipient and additive. This composition may be administered to a patient in need of treatment, thereby achieving therapeutic effects.
- albumin when albumin was added to a composition containing NK cells produced by the method of the present invention, the long-term storage stability, cytotoxicity and cell viability of NK cells could be greatly increased.
- the amount of albumin that is added to the composition of the present invention is not specifically limited, but albumin may be added in an amount of 0.1-5 wt%, and preferably 0.5-2 wt%, based on the total weight of the composition of the present invention.
- the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state.
- the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity.
- the NK cells can be easily stored and supplied in a liquid or frozen state without needing an additional treatment process.
- NK cells produced by the method of the present invention and a composition containing the same may be used for treatment of cancers and infectious diseases.
- NK cells produced by the method of the present invention may be applied to all types of cancers, including solid cancer and blood cancer.
- solid cancer refers to mass-type cancer formed in an organ, unlike blood cancer. Cancers developed in most of organs correspond to solid cancers.
- Cancers which can be treated using NK cells of the present invention are not limited, and preferred examples thereof include, but are not limited to, stomach cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain cancer, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, lymphoma and so on.
- infectious diseases is means to include all diseases which are caused by infection with viruses or pathogenic bacteria and can be infected through respiratory organ, blood or skin contact.
- infectious diseases include, but are not limited to, hepatitis B, hepatitis C, human papilloma virus (HPV) infection, cytomegalovirus infection, viral respiratory disease, influenza and so on.
- Example 1 Culture of NK cells by repeated stimulation(re-stimulation) with feeder cells and evaluation of characteristics
- PBMC Peripheral blood mononuclear cells collected from healthy donors were dispensed into a vial and frozen in liquid nitrogen. One frozen PBMC vial was thawed and transferred into a 50 mL tube, and the cells were suspended in 20 mL of PBS (phosphate buffered saline) containing 1 vol% FBS (fetal serum bovine) or autoplasma and were centrifuged at 1200 rpm at 4 °C for 10 minutes.
- PBS phosphate buffered saline
- FBS fetal serum bovine
- the PBMC pellets were suspended in 10 mL MACS running buffer, and the cells were counted by trypan blue staining.
- 5 ⁇ 10 7 cells were transferred into each of 50 mL fresh tubes and centrifuged at 1200 rpm at 4 °C for 10 minutes.
- PBMC feeder cells were prepared by suspending the pellets in 10 mL of 1 vol% autoplasma-containing CellGro medium (Cellgenix), followed by irradiation with 2000 cGy in a gamma-ray irradiator.
- CD3-depleted cells 400 ⁇ L of running buffer and 100 ⁇ L of CD3 magnetic beads (Miltenyi Biotech) were added to 5 ⁇ 10 7 cell pellets and allowed to react at 4 °C for 20 minutes.
- the reaction material was washed with 20 mL of MACS running buffer, and then centrifuged at 1200 rpm at 4 °C for 10 minutes and suspended in 2 mL of MACS running buffer.
- the cells were separated from the suspension using a CS column (Miltenyi Biotech, 130-041-305) equipped with VarioMACS (Miltenyi Biotech), and the column was washed to reach a final volume of 20 mL, thereby recovering the cells.
- the cells were counted by trypan blue staining, and 1 ⁇ 10 7 cells were dispensed into 50 mL fresh tubes and centrifuged at 1200 rpm at 4 °C for 10 minutes. The cell pellets were suspended in 10 mL of CellGro medium (Cellgenix) containing 1 vol% autoplasma.
- CellGro medium Cellgenix
- IL-2 and 10 ng/mL of OKT-3 were added to a tube containing PBMC feeder cells.
- CellGro medium (Cellgenix) containing 10 mL of PBMC feeder cells, 10 mL of NK cells and 10 mL of 1 vol% autoplasma was added to Nipro 350 bag (Nipro) and subjected to stationary culture in an incubator at 37 °C for 5 days.
- Nipro 350 bag was folded 6 cm from the edge and 5 cm from the bottom so as to reach an area of about 70cm2 and used in stationary culture.
- the same composition as that in the bag culture was used, and culture was performed in a 12-well well plate using CellGro medium containing 0.5 mL of PBMC feeder cells, 0.5 mL of NK cells and 0.5 mL of 1 vol% autoplasma under the same conditions as above.
- the 12-well plate had an area of 3.5-3.8cm2.
- the cells were counted, diluted to about 2 ⁇ 10 5 cells/mL with CellGro medium (Cellgenix) containing 500 IU of IL-2 (Proleukin) and 1 vol% autoplasma and were subjected to stationary culture in a suitable incubator.
- CellGro medium Cellgenix
- IL-2 Proleukin
- the cell concentration and area were adjusted to 2 ⁇ 10 5 cells/mL and 3.5cm2.
- the cells were counted and diluted to 2-5x105 cells/mL with CellGro medium containing 1 vol% autoplasma.
- 1-10-fold feeder cells were prepared and suspended in CellGro medium (Cellgenix) containing 1 vol% autoplasma, followed by irradiation with 2000 cGy in a gamma-ray irradiator. 500 IU of IL-2 and 10 ng/mL of OKT-3 were added thereto, and the two types of cells were co-cultured.
- the cells were re-stimulated with feeder cells, followed by stationary culture. Then, the cells were counted at 2-3 day intervals and subjected to suspension culture until day 21 while they were diluted to 5-10 ⁇ 10 5 cells/mL with CellGro medium (Cellgenix) containing 500 IU of IL-2 and 1 vol% autoplasma. At 21 days of suspension culture, NK cells were collected.
- CellGro medium Cellgenix
- NK cells were suspended to 1-5 ⁇ 10 7 cells/mL in Hatmann's solution (Choongwae Pharmaceutical Corp., Korea) containing 1 wt% albumin (Green Cross Corp.) and were stored at 4 °C.
- Hatmann's solution Choongwae Pharmaceutical Corp., Korea
- 1 wt% albumin Green Cross Corp.
- FIG. 1(a) The results of re-stimulation with feeder cells are shown in FIG. 1(a).
- FIG. 1(a) The results of re-stimulation with feeder cells are shown in FIG. 1(a).
- the existing production method showed an NK cell proliferation of about 161 folds, whereas the proliferation of NK cells was increased by 425 folds upon stimulation twice with feeder cells, and 1,320 folds upon stimulation three times with feeder cells.
- FIG. 1(b) when stimulation with feeder cells was additionally performed at 7 days or 10 days, the proliferation of NK cells was higher than that in the case in which NK cells were cultured without additional stimulation.
- novel culture method which comprises applying additional stimulation with feeder cells and adjusting the amount of medium while maintaining the cell number at a constant level is very effective for the proliferation of NK cells compared to the method which comprises applying stimulation once at an initial stage and proliferating NK cells on the basis of the amount of medium rather than the number of cells.
- a NucleoCounter (Chemometec) system a cell counter method that uses a PI staining solution capable of binding to intracellular nuclei, was used.
- Cells cultured without re-stimulation and cells cultured with re-stimulation at 7 days and 10 days were 10-fold diluted with PBS, and then total cell count and dead cell count were measured using the NucleoCounter system.
- 100 ⁇ L of the 10-fold-diluted cells were mixed with 100 ⁇ L of the lysis buffer Solution A-100 (Chemometec), and 100 ⁇ L of the stabilizing buffer Solution B (Chemometec) was added thereto, after which total cell count was measured using the piston of NucleoCasette. Dead cell count was measured the piston of NucleoCasette without treating the 10-fold-diluted cells.
- the number of viable cells was determined by subtracting the measured dead cell count from the measured total cell count, and then cell viability was calculated using the following equation.
- NK cells cultured for 21 days with re-stimulation by feeder cells showed a high proliferation rate compared to NK cells cultured without re-stimulation while these NK cells showed a high cell viability of about 90%.
- a target cancer cell line (K562, etc.) was recovered, and 3 ⁇ 10 6 cells were placed in a 15 mL tube and centrifuged.
- the cell pellets were suspended in 600 ⁇ L of RPMI medium and 400 ⁇ L of the suspension was transferred into a 15 mL fresh tube, and Calcein-AM (Molecular probe, C34852) was added thereto at a concentration of 50 nM.
- Calcein-AM Molecular probe, C34852
- the cell suspension was stained in an incubator at 37 °C for 20 minutes while light was blocked with a silver foil. Meanwhile, 200 ⁇ L of the remaining cell suspension was added to 800 ⁇ L of RPMI medium at a concentration of 1 ⁇ 10 6 cells/mL.
- the cancer cell line subjected to Calcein-AM staining was washed with 15 mL of RPMI medium and centrifuged, and the pellets were suspended in 2 mL of RPMI medium at a concentration of 1 ⁇ 10 6 cells/mL.
- NK cells were placed in a 15 mL tube and centrifuged, and the pellets were suspended in RPMI medium at a desired ratio relative to the target cancer cell line. 100 ⁇ L of a mixture of the prepared target cancer cell line and the NK cell line was dispensed into each well of a round-bottom 96-well plate. Each well was prepared in duplicate. The plate was incubator at 37 °C for 2 hours in a light-shielded state, and then centrifuged at 2000 rpm for 3 minutes.
- FACS buffer 2.5 wt% FBS in PBS
- 7-AAD 7-AAD
- Cytotoxicity A value - B value
- a value means ratio of target cancer cells killed when NK cells were incubated with target cancer cells (average value of dead target cancer cells stained with both Calcein-AM and 7-AAD-control stained with only Calcein-AM)
- B value means ratio of basically dead target cancer cells (dead target cancer cells stained with both Calcein-AM and 7-AAD-control stained with only Calcein-AM)
- NK cells were collected before and after culture in Example 1(1) and centrifuged at 1200 rpm for 5 minutes, and the medium was removed by suction.
- the cells were diluted with 1 mL of FACS buffer (2.5 % FBS containing PBS), counted and diluted with FACS buffer at a concentration of 5 ⁇ 10 6 cells/mL. 100 ⁇ L of the diluted cell solution was added to each of 5 mL FACS tubes (Falcon, 352052), and the antibodies shown in Table 1 below were added thereto.
- Control tubes were prepared as shown in Table 2 below.
- the tubes shown in Tables 1 and 2 were allowed to stand at refrigeration temperature to stain the cells.
- the stained cells were added to 2 mL of FACS buffer and centrifuged at 1500 rpm for 5 minutes.
- the supernatant was removed, and the pellets were added to 2 mL of FACS buffer and centrifuged at 1500 rpm for 5 minutes.
- the supernatant was removed, and the pellets were suspended in 300 ⁇ L of FACS buffer, after which the cell phenotype was analyzed using FACSCalibur (Becton Dickinson).
- the phenotype corresponding to identification and purity and the phenotype related to the activation and inhibition of NK cells did not significantly differ between the case in which additional stimulation by feeder cells was performed and in the case in which no additional stimulation was performed.
- NK cells produced by the improved culture method comprising re-stimulation with feeder cells show high proliferation rate compared to NK cells cultured by an existing method, the cell viability, cytotoxicity and cell phenotype thereof do not significantly differ from those of the NK cells cultured by the existing method.
- Example 2 In vitro stability (stability in use) resulting from addition of albumin
- Example 1(1) In order to evaluate the stability of cultured cells as a function of the concentration of albumin in Hatmann's solution (2 wt%, 1 wt%, and 0.5 wt%), the cells cultured in Example 1(1) were stored at 4 °C for 72 hours while the in vitro cytotoxicity and in vitro cell viability thereof were evaluated at 24-hour intervals.
- the finally cultured NK cells were centrifuged, and the supernatant was removed.
- the cell pellets were diluted in Hatmann's solution or a Hatmann's solution containing human serum albumin at concentrations of 2 wt%, 1 wt% and 0.5 wt%, thereby making cell dilutions.
- the concentration of the final cell dilution was adjusted to 1.1 ⁇ 10 7 cell/mL by controlling the amount of Hatmann's solution or the human serum albumin-containing Hatmann's solution, and then the cell dispersions were placed in cell culture bags and stored at 4 °C. After 24, 48 and 72 hours, the cells were taken out and the in vitro cytotoxicity (see Example 1(3)) and in vitro cell viability (see Example 1(2)) thereof were evaluated.
- FIG. 5(b) shows cytotoxicity as a function of storage time.
- the NK cells showed a high cytotoxicity of 70% or more even after cold storage for 48 hours.
- FIG. 6 shows a comparison of cumulative data between Hatmann's solution and 1 wt% human albumin-Hatmann's solution.
- FIG. 6(a) when 1 wt% albumin was added, a high cell viability of 80% or more was maintained up to 72 hours. However, in Hatmann's solution, the cell viability decreased rapidly to 60% at 48 hours.
- FIG. 6 shows a comparison of cumulative data between Hatmann's solution and 1 wt% human albumin-Hatmann's solution.
- NKp46 which is connected directly with cytotoxicity was highly expressed in the condition in which 1 wt% albumin was added, and other phenotypes did not significantly differ between the two conditions.
- addition of 1 wt% human albumin to the final NK cell therapeutic agent greatly contributes to ensuring the stability of the NK cells by maintaining the cell viability and cytotoxicity of the NK cells with the passage of time.
- Example 3 NK cell freezing and thawing tests: cell number, yield, phenotype, viability and cytotoxicity
- Example 1(1) The freezing stability of NK cells cultured in Example 1(1) was examined.
- the cell number was adjusted to 2-8 ⁇ 10 7 cells/mL, and the cells to be frozen were transferred into a separate tube and then centrifuged at 1200 rpm for 10 minutes at 4 °C. Freezing in a freezing bag (MEDIRUTION, Korea) was based on 20 mL. The centrifuged cells were suspended well with 14 mL of human serum AB. 4 mL Dextran 40 and 2mL DMSO were mixed with each other and cooled, and the mixed solution was dropped into the prepared cell suspension with stirring. The cells were injected into the freezing bag, and bubbles were removed from the bag. The freezing bag was freezed with controlled-rate freezer (CryoMed freezer, Thermo Scientific) and stored in a liquid nitrogen tank.
- controlled-rate freezer CeryoMed freezer, Thermo Scientific
- the cell phenotype was measured for CD16, NKG2A, NKG2C, NKG2D, NKp30, NKp44, NKp46, CD25, CD62L, CD57 and the like. Finally, the changes in cell yield, viability, cytotoxicity and cell phenotype between before and after freezing were evaluated.
- Example 4 Evaluation of anticancer effect of natural killer cells in lymphoma animal model
- the Raji human B cell lymphoma cell line, ATCC, CCL-86
- SU-DHL-4 human B cell lymphoma cell line, DSMZ, ACC 495 cell lines were cultured in a 5% CO2 incubator at 37 °C using RIMI medium (2 mM L-glutamine, 1 mM sodium pyruvate, 10 wt% FBS, 0.055 mM 2-mercaptoethanol, 100 U/ml penicillin, 100 ug/ml streptomycin).
- mice 6-8-week-old female C.B-17 mice were acclimated for 7 days, and then each of the Raji and SU-DHL-4 cell lines was injected into the tail vein of the mice by a 1 mL syringe at a concentration of 1 ⁇ 10 5 cells/100 ⁇ L.
- mice After xenograft of cancers, the mice were grouped randomly and marked. 400 ⁇ L of PBS was injected into the tail vein of the control group. In the test group, natural killer cells were administered 5 times into the tail vein of the mice at a concentration of 1x107 cells/400 ⁇ L at 2-3-day intervals from 0 day.
- mice After the experiment, the general conditions, mobility and hind extremity paralysis of the mice were examined daily.
- Raji and SU-DHL-4 are administered intravenously into mice which are well known lymphoma models, tumors are created around the spinal cord, and thus the mice show hind extremity paralysis symptoms and lead to death after 2-3 days.
- the development of hind extremity paralysis was evaluated together with survival rate and used as an index of anticancer effect.
- Example 5 Evaluation of anticancer effect of natural killer cells in brain cancer (glioblastoma) animal model
- U-87 MG human glioblastoma cell line, ATCC HTB-14
- ATCC HTB-14 human glioblastoma cell line
- the cells were injected using a Hamilton syringe, and the needle of the syringe was removed for 5 minutes after 5-minute rest. Then, disinfection and suture were performed. The condition and weight of the mice were observed during the test period. The mice were sacrificed according to the test schedule, and the tissue was analyzed.
- NK cells were injected three times at one-week intervals from 1 week after administration of U-87MG.
- the NK cells were injected intracranially and intravenously.
- 1x103, 1x104 and 1 ⁇ 10 5 NK cells were administered, and in the case of intravenous injection, 1 ⁇ 10 5 , 1 ⁇ 10 6 and 1 ⁇ 10 7 NK cells were administered.
- 4 weeks after administration of U-87MG the mice were sacrificed and the anticancer effect of the NK cells was evaluated.
- NK cells were intravenously injected at various points of time as shown in Table 3 below.
- Temozolomide (TMZ) as an anticancer agent was intraperitoneally injected at a dose of 2.5 mg/kg once a day for 5 consecutive days from 3 weeks after administration of U-87MG. At 4 weeks after administration of U-87MG, the mice were sacrificed and the tumor volume was measured.
- hematoxylin-eosin staining was used.
- the brain was extracted from the mice and sectioned at 2 mm intervals. The sections were fixed in 10% buffered formalin solution at 4 °C for 24 hours and embedded in paraffin block.
- the paraffin-embedded tissue was sectioned to 4 ⁇ m, mounted onto coated slide glass and dried overnight. The tissue was de-paraffinized with xylene and rehydrated through a graded alcohol series (100 vol%, 95 vol% and 80 vol% ethanol/distilled water. Then, the tissue was subjected to Gill's hematoxylin-eosin staining, and the degree of staining was examined, followed by dehydration and mounting. The length and width of the tumor in the stained tissue were measured and the tumor volume was calculated using the following equation:
- Tumor volume (mm3) tumor length (mm) ⁇ tumor width (mm) 2 ⁇ 0.5
- NK cells when 1 ⁇ 10 4 and 1 ⁇ 10 5 NK cells were administered intraperitoneally (see FIG. 9) and 1 ⁇ 10 6 and 1 ⁇ 10 7 NK cells were administered intracranially (see FIG. 10), the tumor volume was reduced compared to the control.
- effects resulting from the combined administration of NK cells and the anticancer agent and the time point of administration were observed (see FIG. 11), it could be seen that the tumor volume was smaller when TMZ and NK cells were administered in combination than when they were administered alone.
- NK cells when NK cells were injected three times within 1 week after administration of cancer, the tumor volume was most significantly reduced, suggesting that the best effect was shown.
- TUNEL terminal deoxynucleotidyl mediated deoxyuridine triphosphate nick-end labeling assay
- paraffin-embedded tissue (4 mm) was mounted onto coated slide glass and dried overnight.
- the tissue was de-paraffinized with xylene and rehydrated through a graded alcohol series (100 vol%, 95 vol% and 80 vol% ethanol/distilled water, followed by washing with PBS (pH 7.5).
- the degree of cell death in the tissue was examined using a TUNEL kit (Invitrogen).
- the stained slide was counterstained with Gill's hematoxylin for 1 minute and mounted.
- the stained slide was photographed with a microscope at 400x magnification with respect to the cancer edge to obtain 10 photographs, and the cells were counted with respect to the cells showing a positive response, and the measurements were averaged.
- Example 6 Evaluation of anticancer effect of NK cells in ovarian cancer animal model
- Luciferase gene was cloned into a pGL3 vector and transiently transfected into an OVCAR-3 cell line.
- Cell lines showing the expression of luciferase were primarily selected using luciferin, and cell lines having the phenotypes and NK cytotoxicities similar to those of OVCAR-3 were secondarily selected.
- the OVCAR-3-Luc (human ovarian cancer cell line, KTCC (Korean Cell Line Bank) 30162) cell line was incubated at 37 °C in a 5% CO 2 incubator using RIMI medium (2 mM L-glutamine, 1 mM sodium pyruvate, 10 % FBS, 0.055 mM 2-mercaptoethanol, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 100 ⁇ g/mL G418).
- RIMI medium 2 mM L-glutamine, 1 mM sodium pyruvate, 10 % FBS, 0.055 mM 2-mercaptoethanol, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 100 ⁇ g/mL G418).
- mice 6-8-week-old female C.B-17 SCID mice were acclimated for 7 days, and the OVCAR-3-Luc cell line was injected intraperitoneally into the mice at a concentration of 5 ⁇ 10 6 cells/100 ⁇ L.
- mice After xenograft of cancers, the mice were grouped randomly and marked.
- the control group was injected intraperitoneally with 200 ⁇ L of Hatmann's solution (Choongwae Pharmaceutical Corp., Korea).
- Hatmann's solution Choongwae Pharmaceutical Corp., Korea.
- the NK cell-treated group was intraperitoneally injected five times with 1 ⁇ 10 7 NK cells/200 ⁇ L at 2-3-day intervals from 1 week after xenograft of cancers.
- Luciferin was administered intraperitoneally to the mice, and luciferase images were photographed using an IVIS imaging system (Xenogen) at 7-day intervals. 8 weeks after xenograft of the cancer, the abdomens of the mice of all the groups were open, and the volumes of tumors were measured.
- the cancer cells spread throughout the abdominal cavity, and the luciferase image appeared to be large. However, after 7 days, the cancer cells were engrafted, and thus the luciferase level decreased. After 7 days, in the group administered with NK cells, the luciferase level decreased continuously up to 23 days, whereas in the negative control group, the luciferase level increased. (see FIG. 12 (a)).
- mice were sacrificed, the tumor was extracted, and the volume and weight of the tumor were measured (see FIG. 12(b)). It was observed that the weight of the tumor in the NK cell-administered group decreased by 54.91% compared to that in the negative control group. In other words, the tumor volume in the NK cell-administered group significantly decreased compared to that in the negative control group. This suggests that when NK cells are administered intraperitoneally to a model having ovarian cancer metastasized to the abdominal cavity, they inhibit the growth of the tumor.
- Example 7 Evaluation of anticancer effect of NK cells in a human liver cancer animal model
- a human tumor xenograft mouse model was constructed and the NK cells were administered intravenously.
- 6 ⁇ 10 6 cells of SNU-354 cells, a human liver cancer cell line were implanted subcutaneously to the side of a nude mouse.
- NK cells Two hours after xenografting of SNU-354 cells, 1 ⁇ 10 6 cells or 1 ⁇ 10 7 cells of NK cells were administered in 200 ⁇ L via the tail vein of the mouse. After the first administration, the same dose of NK cells was injected 3 times more at an interval of a week.
- NK cells To evaluate the toxicity of NK cells during the experiment, the general conditions were observed daily and the animal weight and tumor volume were measured 11 times (day 0, 7, 9, 12, 14, 16, 19, 21, 23, 26, and 28) until the end of the experiments. After 28 days, the animals were sacrificed and the weights of the extracted tumors were measured.
- the tumor volume of the NK cell-administered group decreased by 37.7% (1 ⁇ 10 6 cells/mouse) and 50.6% (1 ⁇ 10 7 cells/mouse), compared with that of the negative control group (Fig. 13).
- the tumor weight of the NK cell-administered group decreased by 36.0% (1 ⁇ 10 6 cells/mouse) and 50.2% (1 ⁇ 10 7 cells/mouse), compared with that of the negative control group (Fig. 13).
- NK cells may be used for liver cancer treatment.
- Example 8 Evaluation of anticancer effect of NK cells in neuroblastoma animal model
- NB-1691luc cell line prepared by transfection with luciferase gene into NB-1691(human neuroblastoma cell line, from St. Jude Children's Research Hospital), was incubated at 37 °C in a 5% CO 2 incubator using RIMI medium (2 mM L-glutamine, 1 mM sodium pyruvate, 10 % FBS, 0.055 mM 2-mercaptoethanol, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 100 ⁇ g/mL G418).
- RIMI medium 2 mM L-glutamine, 1 mM sodium pyruvate, 10 % FBS, 0.055 mM 2-mercaptoethanol, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 100 ⁇ g/mL G418).
- mice 7-week-old female C.B-17 SCID mice were acclimated for 7 days, and the NB-1691luc cell line was injected into the tail vein of mice at a concentration of 5 ⁇ 10 5 cells/100 ⁇ L.
- mice After xenograft of cancers, the mice were grouped randomly and marked.
- the control group was injected 200 ⁇ L of Hatmann's solution (Choongwae Pharmaceutical Corp., Korea) into the vein of tail.
- the NK cell-treated group was injected five times with 1 ⁇ 10 7 NK cells/200 ⁇ L at 2-3-day intervals from 1 week after xenograft of cancers into the vein of tail.
- mice After xenograft of NB-1691luc, the general conditions and mobility of the mice were observed daily. To follow up tumor growth, Luciferin was administered intraperitoneally to the mice and luciferase images were photographed using an IVIS imaging system (Xenogen) at 7-day intervals.
- IVIS imaging system Xenogen
- Example 9 Evaluation of efficacy of NK cells on various cancer cell lines and virus infected cell lines in vitro
- NK cells prepared as described in Example 1 By using NK cells prepared as described in Example 1, cytotoxicity of NK cells were evaluated as described in Example 1(3).
- the NK cells’ ability of cytokines secretion was measured as follows;
- NK cells Preparing NK cells(5 ⁇ 10 6 cell/mL) and target cancer cell lines(5 ⁇ 10 6 cell/mL), and adding the prepared NK cells and target cancer cell lines into the round-bottomed 96-well plate. To avoid secretion of cytokines accumulated in the cellof GolgiStop(BD Pharmingen, 554724) was added simultaneously.
- Well 1 Suspended NK cells 100 ⁇ L, RPMI medium 100 ⁇ L, anti-human CD107a-APC (BD Pharmingen, 560664) 1 ⁇ L
- Well 2 Suspended NK cells 100 ⁇ L, suspended target cancer cell line 100 ⁇ L, anti-human CD107a-APC (BD Pharmingen, 560664) 1 ⁇ L
- Well 3 Suspended NK cells 100 ⁇ L, suspended target cancer cell line 100 ⁇ L, APC mouse IgG1 k isotope control (BD Pharmingen, 555751) 5 ⁇ L
- the 96 well plate was wrapped by foil, and then stored in 37 °C incubator for 4 hours. After 4 hours, supernatant of 96 well plate was removed, and 100 ⁇ L FACS buffer, 7-AAD (BD, 559925) 5 ⁇ L, anti-human CD3-PerCP-Cy5.5 (eBioscience, 45-0036-42) 1 ⁇ L and anti-human CD56-APC-eFluor780 (eBioscience, 47-0567-42) 1 ⁇ L was added to each well.
- FACS buffer 7-AAD (BD, 559925) 5 ⁇ L
- anti-human CD3-PerCP-Cy5.5 eBioscience, 45-0036-42
- anti-human CD56-APC-eFluor780 eBioscience, 47-0567-42
- the 96-well plate was stained by storing for 30 minutes in 4 °C, and then 200 ⁇ L FACS buffer was added and centrifuged(2000 rpm) for 3 minutes(2 times).
- Well 1 & 2 diluted Perm/Wash 100 ⁇ L, anti-human IFN-g-FITC (BD, 554700) 1 ⁇ L, anti-human TNF-a-PE-Cy7 (eBioscience, 25-7349-82) 1 ⁇ L
- Well 3 diluted Perm/Wash 100 ⁇ L, FITC mouse IgG1 k isotope control (BD, 555748) 5 ⁇ L, PE-Cy7 mouse IgG1 k isotope control (BD, 557872) 5 ⁇ L
- Cytokine was stained by storing the 96-well plate for 30 minutes in 4 °C. After staining, 200 ⁇ L of Perm/Wash buffer (BD, 51-2090KZ) which was diluted 10 times by distilled water was added to each well and the 96-well plate was centrifuged (2000 rpm) for 3 minutes (2 times).
- Perm/Wash buffer BD, 51-2090KZ
- FIG. 15 shows the in-vitro efficacy (cytotoxicity and ability of cytokine secretion) of NK cells on various cancer cell lines and virus infected cell lines as follows;
- Huh-7 cell lines HCC, Hepatocellular carcinoma
- NK cells showed excellent cell cytotoxicity to most of cancer cell lines. Moreover, NK cells showed good cytotoxicity to virus infected cell lines.
- NK cells showed the strong cytokine secretion ability against K562 cell lines and virus infected cancer cell lines (HBV and HCV infected HCC cell lines).
- NK cells produced according to the present invention have an excellent efficacy (cytotoxicity and ability of cytokine secretion) against various cancer cell lines and virus infected cell lines.
- NK cells produced by the method of the present invention have excellent long-term storage stability, because the cell viability and cytotoxicity thereof can be stably maintained over a long period of time.
- the cytotoxicity and cell viability can be greatly increased. Also, due to the characteristics of the production method of the present invention, the cytotoxicity (i.e., therapeutic effect) and cell viability of the NK cells can be maintained even when they are thawed after frozing. Thus, the NK cells can be easily stored and supplied in a liquid or frozen state without needing an additional treatment process.
- the NK cells produced by the present invention can stably exhibit their effect in vivo , and thus a composition containing the same as an active ingredient can be effectively used for treatment of cancers and infectious diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
Abstract
Description
Claims (18)
- A method for producing NK cells, comprising the steps of:(i) isolating peripheral blood leukocytes and NK cells from human peripheral blood;(ii) carrying out stationary culture of NK cells in a medium containing anti-CD3 antibody, cytokine and feeder cells to stimulate by cell-cell contact;(iii) after completion of stationary culture in step (ii), re-stimulating the cells by addition of cytokine, anti-CD3 antibody and feeder cells, and carrying out stationary culture to stimulate cause cell-cell contact;(iv) after completion of the stationary culture, adding to the cells a medium containing cytokine and the like required for stationary or suspension culture, and carrying out stationary or suspension culture while maintaining cell concentration and cytokine concentration at constant levels.
- The method of claim 1, wherein step (iii) of re-stimulating the cells and carrying out stationary culture is repeated twice or more.
- The method of claim 1, wherein the stationary culture in step (ii) is performed for 2-15 days, and the stationary culture in step (iii) is performed for 2-7 days.
- The method of claim 1, wherein the suspension culture in step (iv) is performed by using a reactor selected from the group consisting of a shaking flask, a shaking incubator, a fermentor, a T-flask, and a disposable cell culture bag.
- The method of claim 1, wherein the stationary culture in step (ii) or (iii) and the stationary or suspension culture in step (iv) are performed in a same or different reactor.
- The method of claim 1, the concentrations of cell and cytokine in the medium are measured during the stationary or suspension culture in step (iv), and the medium containing cytokine are added in order to maintain cell and cytokine concentration at constant levels.
- The method of claim 1, wherein the anti-CD3 antibody is one or more selected from the group consisting of OKT3, UCHT1, and HIT3a.
- The method of claim 7, wherein the anti-CD3 antibody is OKT-3 antibody.
- The method of claim 1, wherein the cytokine is one or more selected from the group consisting of interleukin-2 (IL-2), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18), and interleukin-21 (IL-21).
- The method of claim 9, wherein the cytokine is IL-2.
- The method of claim 1, wherein the feeder cells are inactivated peripheral blood mononuclear cells.
- An NK cell produced by the method of any one of claims 1 to 11.
- A composition for treating cancers or infectious diseases, which contains the NK cell of claim 12.
- The composition of claim 13, further containing albumin.
- The composition of claim 14, wherein the albumin is comprised in an amount of 0.1-5 wt% based on the total weight of the composition.
- The composition of claim 13, wherein the cancers are selected from the group consisting of stomach cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain cancer, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, and lymphoma.
- The composition of claim 13, wherein the infectious diseases are selected from the group consisting of hepatitis B, hepatitis C, human papilloma virus (HPV) infection, cytomegalovirus infection, viral respiratory disease, influenza.
- A liquid or frozen formulation comprising the composition of claim 13.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020147020574A KR101644984B1 (en) | 2011-12-22 | 2012-12-18 | Method For Producing Natural Killer Cells, Natural Killer Cells Produced Thereby, And Composition For Treating Cancers And Infectious Diseases Containing The Same |
JP2014548657A JP6010136B2 (en) | 2011-12-22 | 2012-12-18 | Method for producing natural killer cell, natural killer cell produced by the method, and composition for treating tumor and infectious disease containing the same |
AU2012354438A AU2012354438B2 (en) | 2011-12-22 | 2012-12-18 | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same |
NO12859499A NO2794859T3 (en) | 2011-12-22 | 2012-12-18 | |
EP12859499.1A EP2794859B1 (en) | 2011-12-22 | 2012-12-18 | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same |
ES12859499.1T ES2652666T3 (en) | 2011-12-22 | 2012-12-18 | Production process of natural cytolytic lymphocytes, natural cytolytic lymphocytes produced in this way and composition for the treatment of cancers and infectious diseases containing them |
US14/367,813 US9834753B2 (en) | 2011-12-22 | 2012-12-18 | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same |
CN201280070546.3A CN104204194B (en) | 2011-12-22 | 2012-12-18 | Produce the method for natural killer cells, by the natural killer cells of this method production and the composition for treating cancer and infectious diseases comprising the natural killer cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0140361 | 2011-12-22 | ||
KR20110140361 | 2011-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013094988A1 true WO2013094988A1 (en) | 2013-06-27 |
Family
ID=48668805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/011114 WO2013094988A1 (en) | 2011-12-22 | 2012-12-18 | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same |
Country Status (9)
Country | Link |
---|---|
US (1) | US9834753B2 (en) |
EP (1) | EP2794859B1 (en) |
JP (1) | JP6010136B2 (en) |
KR (1) | KR101644984B1 (en) |
CN (1) | CN104204194B (en) |
AU (1) | AU2012354438B2 (en) |
ES (1) | ES2652666T3 (en) |
NO (1) | NO2794859T3 (en) |
WO (1) | WO2013094988A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103923879A (en) * | 2014-04-29 | 2014-07-16 | 湖北华赛生物医药技术有限公司 | Preparation method and application of NK cytokine mixture |
CN104593324A (en) * | 2014-11-28 | 2015-05-06 | 广州赛莱拉干细胞科技股份有限公司 | Natural killer cell culture medium and natural killer cell amplification culture method |
WO2016085248A1 (en) | 2014-11-26 | 2016-06-02 | Green Cross Lab Cell Corporation | Method for culturing natural killer cells using t cells |
EP3252152A4 (en) * | 2015-01-27 | 2018-02-28 | Korea Research Institute of Bioscience and Biotechnology | Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent |
EP3399027A1 (en) * | 2017-05-04 | 2018-11-07 | Medizinische Hochschule Hannover | Stem-cell derived myeloid cells, generation and use thereof |
CN108934158A (en) * | 2016-02-01 | 2018-12-04 | Gc细胞治疗 | Cell cryopreservation culture media composition and its application |
CN110305843A (en) * | 2019-07-12 | 2019-10-08 | 赛德特生物科技开发有限公司 | Immunocyte of autoimmune disease and the preparation method and application thereof can be improved |
JP2021073169A (en) * | 2015-12-16 | 2021-05-13 | ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ | Inhibition of cytokine-induced SH2 protein in NK cells |
US11278569B2 (en) | 2016-11-14 | 2022-03-22 | Paean Biotechnology Inc. | Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same |
RU2777371C2 (en) * | 2016-11-14 | 2022-08-02 | Пэан Байотекнолоджи Инк. | Natural killer cell containing exogenous mitochondria, and pharmaceutical composition including such a cell |
US11970547B2 (en) | 2017-11-14 | 2024-04-30 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
EP4117687A4 (en) * | 2020-03-11 | 2024-10-02 | Res Inst Nationwide Childrens Hospital | Nk cells and uses thereof for treatment of microbial infections |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101706524B1 (en) * | 2014-12-03 | 2017-02-14 | 주식회사 녹십자랩셀 | Efficient Method for Preparing of Stable Natural Killer Cells |
CN104789527B (en) * | 2015-05-15 | 2018-05-29 | 江苏杰晟生物科技有限公司 | A kind of preparation method and its reagent kit product of self natural killer cells cocktail type culture |
KR101909879B1 (en) * | 2015-06-24 | 2018-10-19 | 주식회사 차바이오텍 | Method and Composition for Proliferating of Natural Killer Cell |
WO2016209021A1 (en) * | 2015-06-24 | 2016-12-29 | 주식회사 차바이오텍 | Method for proliferating natural killer cells and composition for proliferating natural killer cells |
JP6073417B2 (en) * | 2015-06-26 | 2017-02-01 | チャ バイオテック カンパニー リミテッド | Spontaneous killing cell proliferation method and composition for spontaneous killing cell proliferation |
WO2017003153A1 (en) * | 2015-06-29 | 2017-01-05 | 주식회사 녹십자랩셀 | Method for producing natural killer cells from cord blood monocytes or cells derived therefrom |
EP3138905A1 (en) * | 2015-09-04 | 2017-03-08 | Miltenyi Biotec GmbH | Method for natural killer cell expansion |
EP3411414A4 (en) * | 2016-02-05 | 2019-10-23 | Washington University | Compositions and methods for targeted cytokine delivery |
KR101683614B1 (en) * | 2016-02-15 | 2016-12-07 | 신동혁 | Culture Media Kits for NK cell Cultivation and NK cell Culture Method using the Same |
CN105754942A (en) * | 2016-05-18 | 2016-07-13 | 天津普瑞赛尔生物科技有限公司 | Method for amplifying NK cells in vitro and NK cells obtained by same |
CN105925527A (en) * | 2016-05-19 | 2016-09-07 | 成都百赛泰科生物科技有限公司 | Kit for preparing NK cells and application method thereof |
CN107686828A (en) * | 2016-08-04 | 2018-02-13 | 英普乐孚生物技术(上海)有限公司 | A kind of NK cell non-serum culture mediums |
CN106434554B (en) * | 2016-08-31 | 2019-07-26 | 北京同立海源生物科技有限公司 | The preparation method of NK cell |
US10300089B2 (en) * | 2016-11-08 | 2019-05-28 | University Of Central Florida Research Foundation, Inc. | Methods for high scale therapeutic production of memory NK cells |
CN106834227B (en) * | 2016-12-26 | 2020-01-24 | 深圳精准医疗科技有限公司 | In vitro purification method of natural killer cells |
AU2018271755B2 (en) * | 2017-05-26 | 2021-12-23 | Green Cross Lab Cell Corporation | Method for culturing natural killer cell, using transformed T cell |
CN107267463A (en) * | 2017-08-23 | 2017-10-20 | 安徽惠恩生物科技股份有限公司 | A kind of Car NK cell preparation methods for breast cancer |
CN107595865B (en) * | 2017-09-25 | 2018-08-14 | 徐州佳生医药科技有限公司 | A kind of CCR5 expression accelerating agents and the application in preparing the drug for promoting NK cell-penetrating blood-brain barriers |
KR102265437B1 (en) | 2017-11-24 | 2021-06-15 | 의료법인 성광의료재단 | Composition for culturing NK cell and method for culturing NK cell using the same |
KR102014467B1 (en) * | 2017-12-14 | 2019-08-26 | (주)녹십자웰빙 | Cosmetic composition and pharmaceutical composition for improving atopic dermatis, alopetic, wound, or skin wrinkle |
WO2019152513A1 (en) * | 2018-01-31 | 2019-08-08 | Nantkwest, Inc. | Use of 5% human albumin in wash and harvest media |
NZ766453A (en) | 2018-02-01 | 2022-02-25 | Nkmax Co Ltd | Method of producing natural killer cells and composition for treating cancer |
KR102232321B1 (en) * | 2018-03-23 | 2021-03-26 | 주식회사 녹십자랩셀 | Method for Preparing NK Cell |
WO2019182392A1 (en) | 2018-03-23 | 2019-09-26 | 주식회사 녹십자랩셀 | Method for producing natural killer cells |
WO2019213610A1 (en) * | 2018-05-03 | 2019-11-07 | Board Of Regents, The University Of Texas System | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
CN108815186A (en) * | 2018-06-14 | 2018-11-16 | 上海鸣大生物科技有限公司 | A kind of drug and preparation method and application treated HPV persistent infection and cause disease |
KR20200030337A (en) * | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell |
CN109762785B (en) * | 2018-12-10 | 2022-06-24 | 苏州近岸蛋白质科技股份有限公司 | Method for efficiently applying to in-vitro culture of human NK cell non-trophoblast |
WO2020189990A1 (en) * | 2019-03-15 | 2020-09-24 | (주)테라베스트 | Cell composition, method for producing same, and pharmaceutical composition for preventing or treating atopic disease comprising same |
KR102137954B1 (en) * | 2019-05-16 | 2020-07-27 | (주)녹십자셀 | Activated lymphocyte including cytokine induced killer cell and preparing method thereof |
AU2020387322B2 (en) * | 2019-11-20 | 2024-06-06 | Gi Cell, Inc. | Composition for culturing natural killer cells and method for preparing natural killer cells by using same |
CN114929249A (en) * | 2019-11-29 | 2022-08-19 | Nkmax有限公司 | Methods of generating natural killer cells and compositions thereof |
KR102111283B1 (en) | 2019-12-12 | 2020-05-15 | 주식회사 이뮤니스바이오 | Shaking culture method of immune cells |
WO2021178890A1 (en) | 2020-03-06 | 2021-09-10 | Sorrento Therapeutics, Inc. | Innate immunity killer cells targeting psma positive tumor cells |
KR20220036287A (en) * | 2020-09-15 | 2022-03-22 | 주식회사 티에스바이오 | Manufacturing method of high purity and high efficiency natural killer cells and uses thereof |
CN116635064A (en) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | Chimeric antigen receptor systems with adaptive receptor specificity |
KR20230039789A (en) * | 2021-09-10 | 2023-03-21 | 한국생명공학연구원 | Method for producing induced natural killer cells and their use for preventing or treating infectious diseases |
WO2023081813A1 (en) | 2021-11-05 | 2023-05-11 | St. Jude Children's Research Hospital, Inc. | Zip cytokine receptors |
WO2023147347A2 (en) * | 2022-01-25 | 2023-08-03 | The Regents Of The University Of California | Crispr-mediated deletion of fli1 in nk cells |
WO2023240182A1 (en) | 2022-06-08 | 2023-12-14 | St. Jude Children's Research Hospital, Inc. | Disruption of kdm4a in t cells to enhance immunotherapy |
WO2024059787A1 (en) | 2022-09-16 | 2024-03-21 | St. Jude Children's Research Hospital, Inc. | Disruption of asxl1 in t cells to enhance immunotherapy |
WO2024175080A1 (en) * | 2023-02-24 | 2024-08-29 | 士泽生物医药(苏州)有限公司 | Kit for inducing stem cells to differentiate into nk cells, use of kit, and use of combination of nk cells and tmz in treatment for tmz drug-resistant gbm |
CN118109410B (en) * | 2024-04-26 | 2024-07-16 | 赛奥斯博生物科技(北京)有限公司 | Preparation method and application of natural killer cell exosome |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030068306A1 (en) | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
KR20080008060A (en) * | 2006-07-19 | 2008-01-23 | 전남대학교산학협력단 | A method for production of natural killer cell |
WO2008023874A1 (en) | 2006-08-23 | 2008-02-28 | Binex Co., Ltd. | Manufacturing method of activated lymphocytes for immunotherapy |
WO2008138214A1 (en) | 2007-05-09 | 2008-11-20 | Yu Wang | A method for activation and expansion of lymphocytes with high efficiency and the culture sysytem thereof |
WO2009151183A1 (en) | 2008-06-10 | 2009-12-17 | Nkbio Co., Ltd | A medium composition for cultivating self activated lymphocyte |
WO2010013947A2 (en) | 2008-07-29 | 2010-02-04 | 주식회사 녹십자 | Growth method for natural killer cells |
KR101035556B1 (en) * | 2008-05-22 | 2011-05-23 | 재단법인 목암생명공학연구소 | Method of preparing natural killer cells, natural killer cells prepared by the method, and composition for treatment of solid cancer containing same |
KR20110132618A (en) * | 2009-03-26 | 2011-12-08 | 아바리스 아베 | Expansion of nk cells |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766601A (en) * | 1990-08-08 | 1998-06-16 | University Of Massachusetts Medical Center | Cross-reactive influenza a immunization |
WO1997005239A1 (en) * | 1995-07-25 | 1997-02-13 | Celltherapy, Inc. | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
CA2247131A1 (en) * | 1996-03-04 | 1997-09-12 | Targeted Genetics Corporation | Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes |
EP0947581A4 (en) * | 1996-08-08 | 2004-07-28 | Mitsubishi Pharma Corp | Culture medium and use of the same |
WO2005007116A2 (en) * | 2003-07-18 | 2005-01-27 | Valeocyte Therapies Llc | Artificial antigen presenting cell devices |
JP4953403B2 (en) * | 2007-11-05 | 2012-06-13 | 恒雄 倉持 | Method for producing cells for cancer immunotherapy |
KR101043588B1 (en) | 2008-07-25 | 2011-06-22 | 재단법인 철원플라즈마 산업기술연구원 | Method Of Forming Ceramic Coating Layer having the Resistant Plasma |
JP5792622B2 (en) * | 2009-09-11 | 2015-10-14 | タカラバイオ株式会社 | Method for producing natural killer cells |
US20130011376A1 (en) * | 2009-12-29 | 2013-01-10 | Gamida Cell Ltd. | Methods for Enhancing Natural Killer Cell Proliferation and Activity |
EP2702145A1 (en) * | 2011-04-28 | 2014-03-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for preparing accessory cells and uses thereof for preparing activated nk cells |
-
2012
- 2012-12-18 AU AU2012354438A patent/AU2012354438B2/en active Active
- 2012-12-18 NO NO12859499A patent/NO2794859T3/no unknown
- 2012-12-18 WO PCT/KR2012/011114 patent/WO2013094988A1/en active Application Filing
- 2012-12-18 CN CN201280070546.3A patent/CN104204194B/en active Active
- 2012-12-18 US US14/367,813 patent/US9834753B2/en active Active
- 2012-12-18 JP JP2014548657A patent/JP6010136B2/en active Active
- 2012-12-18 KR KR1020147020574A patent/KR101644984B1/en active IP Right Grant
- 2012-12-18 ES ES12859499.1T patent/ES2652666T3/en active Active
- 2012-12-18 EP EP12859499.1A patent/EP2794859B1/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030068306A1 (en) | 2001-09-14 | 2003-04-10 | Dilber Mehmet Sirac | Medium |
KR20080008060A (en) * | 2006-07-19 | 2008-01-23 | 전남대학교산학협력단 | A method for production of natural killer cell |
WO2008023874A1 (en) | 2006-08-23 | 2008-02-28 | Binex Co., Ltd. | Manufacturing method of activated lymphocytes for immunotherapy |
WO2008138214A1 (en) | 2007-05-09 | 2008-11-20 | Yu Wang | A method for activation and expansion of lymphocytes with high efficiency and the culture sysytem thereof |
KR101035556B1 (en) * | 2008-05-22 | 2011-05-23 | 재단법인 목암생명공학연구소 | Method of preparing natural killer cells, natural killer cells prepared by the method, and composition for treatment of solid cancer containing same |
WO2009151183A1 (en) | 2008-06-10 | 2009-12-17 | Nkbio Co., Ltd | A medium composition for cultivating self activated lymphocyte |
WO2010013947A2 (en) | 2008-07-29 | 2010-02-04 | 주식회사 녹십자 | Growth method for natural killer cells |
KR101133185B1 (en) * | 2008-07-29 | 2012-04-06 | 서울대학교병원 | Method for Proliferating Natural Killer cell |
KR20110132618A (en) * | 2009-03-26 | 2011-12-08 | 아바리스 아베 | Expansion of nk cells |
Non-Patent Citations (2)
Title |
---|
LI, XIAO-HONG ET AL.: "Ex vivo expansion of highly purified NK cells from human peripheral blood", ZHONGGUO SHIYAN XUEYEXUE ZAZHI - JOURNAL OF EXPERIMENTAL HEMATOLOGY, ZHONGGUO SHIYAN XUEYEXUE ZAZHISHE, BEIJING, CN, vol. 15, no. 2, 1 April 2007 (2007-04-01), pages 373 - 377, XP009160095 |
See also references of EP2794859A4 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103923879B (en) * | 2014-04-29 | 2016-03-30 | 湖北华赛生物医药技术有限公司 | A kind of preparation method of NK cytokine mixture and application thereof |
CN103923879A (en) * | 2014-04-29 | 2014-07-16 | 湖北华赛生物医药技术有限公司 | Preparation method and application of NK cytokine mixture |
EP3878950A1 (en) | 2014-11-26 | 2021-09-15 | Green Cross Lab Cell Corporation | Method for culturing natural killer cells using t cells |
WO2016085248A1 (en) | 2014-11-26 | 2016-06-02 | Green Cross Lab Cell Corporation | Method for culturing natural killer cells using t cells |
CN107002039A (en) * | 2014-11-26 | 2017-08-01 | Gc细胞治疗 | The method for being used to cultivate NK using T cell |
JP2018501779A (en) * | 2014-11-26 | 2018-01-25 | グリーン クロス ラボ セル コーポレーションGreen Cross Lab Cell Corporation | Method for culturing natural killer cells using T cells |
EP3224349A4 (en) * | 2014-11-26 | 2018-06-27 | Green Cross Lab Cell Corporation | Method for culturing natural killer cells using t cells |
US11766456B2 (en) | 2014-11-26 | 2023-09-26 | GC Cell Corporation | Method for culturing natural killer cells using T cells |
CN107002039B (en) * | 2014-11-26 | 2021-04-23 | Gc细胞治疗 | Method for culturing natural killer cells using T cells |
AU2015354941B2 (en) * | 2014-11-26 | 2018-11-15 | GC Cell Corporation | Method for culturing natural killer cells using T cells |
CN104593324A (en) * | 2014-11-28 | 2015-05-06 | 广州赛莱拉干细胞科技股份有限公司 | Natural killer cell culture medium and natural killer cell amplification culture method |
EP3252152A4 (en) * | 2015-01-27 | 2018-02-28 | Korea Research Institute of Bioscience and Biotechnology | Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent |
JP2021073169A (en) * | 2015-12-16 | 2021-05-13 | ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ | Inhibition of cytokine-induced SH2 protein in NK cells |
EP3412149A4 (en) * | 2016-02-01 | 2019-09-18 | Green Cross Lab Cell Corporation | Medium composition for cryopreservation of cell and use thereof |
CN108934158A (en) * | 2016-02-01 | 2018-12-04 | Gc细胞治疗 | Cell cryopreservation culture media composition and its application |
US11278569B2 (en) | 2016-11-14 | 2022-03-22 | Paean Biotechnology Inc. | Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same |
RU2777371C2 (en) * | 2016-11-14 | 2022-08-02 | Пэан Байотекнолоджи Инк. | Natural killer cell containing exogenous mitochondria, and pharmaceutical composition including such a cell |
WO2018202881A1 (en) * | 2017-05-04 | 2018-11-08 | Medizinische Hochschule Hannover | Stem-cell derived myeloid cells, generation and use thereof |
EP3399027A1 (en) * | 2017-05-04 | 2018-11-07 | Medizinische Hochschule Hannover | Stem-cell derived myeloid cells, generation and use thereof |
US11970547B2 (en) | 2017-11-14 | 2024-04-30 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
CN110305843B (en) * | 2019-07-12 | 2020-06-02 | 赛德特生物科技开发有限公司 | Immune cell capable of improving autoimmune diseases and preparation method and application thereof |
CN110305843A (en) * | 2019-07-12 | 2019-10-08 | 赛德特生物科技开发有限公司 | Immunocyte of autoimmune disease and the preparation method and application thereof can be improved |
EP4117687A4 (en) * | 2020-03-11 | 2024-10-02 | Res Inst Nationwide Childrens Hospital | Nk cells and uses thereof for treatment of microbial infections |
Also Published As
Publication number | Publication date |
---|---|
US9834753B2 (en) | 2017-12-05 |
JP6010136B2 (en) | 2016-10-19 |
EP2794859B1 (en) | 2017-09-20 |
JP2015502756A (en) | 2015-01-29 |
EP2794859A1 (en) | 2014-10-29 |
NO2794859T3 (en) | 2018-02-17 |
KR101644984B1 (en) | 2016-08-12 |
AU2012354438A1 (en) | 2014-07-10 |
KR20140123503A (en) | 2014-10-22 |
ES2652666T3 (en) | 2018-02-05 |
CN104204194B (en) | 2018-08-03 |
US20150118207A1 (en) | 2015-04-30 |
CN104204194A (en) | 2014-12-10 |
AU2012354438B2 (en) | 2016-03-31 |
EP2794859A4 (en) | 2015-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013094988A1 (en) | Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same | |
WO2016122147A1 (en) | Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent | |
US20210361708A1 (en) | Methods for the production of tcr gamma delta + t cells | |
Badillo et al. | Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response | |
WO2016209021A1 (en) | Method for proliferating natural killer cells and composition for proliferating natural killer cells | |
WO2018097540A2 (en) | Serum-free immune cell-culturing medium-added kit, method for culturing immune cells by using same kit, serum-free immune cell culture obtained by same kit or culturing method, and cosmetic composition comprising same culture | |
WO2016085248A1 (en) | Method for culturing natural killer cells using t cells | |
US7553661B2 (en) | Stromal antigen-presenting cells and use thereof | |
WO2012111997A2 (en) | Cell therapy composition for preventing or treating immune disease comprising mesenchymal stem cells and immunoregulatory t-cells as active ingredient | |
Hu et al. | Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma | |
WO2020101361A1 (en) | Method for culturing cord blood-derived natural killer cells using transformed t-cells | |
KR20160066837A (en) | Efficient Method for Preparing of Stable Natural Killer Cells | |
Watchmaker et al. | Memory CD8+ T cells protect dendritic cells from CTL killing | |
JP2018538245A (en) | Methods for enriching and expanding viral antigen-specific T cells | |
Paunicka et al. | Role of IFN-γ in the establishment of anterior chamber-associated immune deviation (ACAID)-induced CD8+ T regulatory cells | |
WO2019182392A1 (en) | Method for producing natural killer cells | |
WO2017146538A1 (en) | Pharmaceutical composition for preventing or treating regulatory t cell-mediated diseases | |
US20100215628A1 (en) | Method for preparing cell populations with anti-tumor immune response activity | |
WO2023128733A1 (en) | Method for expansion culture of gamma-delta t cell | |
WO2017003153A1 (en) | Method for producing natural killer cells from cord blood monocytes or cells derived therefrom | |
WO2016117960A1 (en) | Mesenchymal stem cells over-expressed by grim19 efficacious in treating immune disease, and use thereof | |
WO2015023165A1 (en) | Inflammation-controlling composite and stabilized mesenchymal stem cells having optimized immunity control function by blocking stat3 signal molecule | |
JP6447947B2 (en) | Efficient NKT cell activation technology | |
WO2013162330A1 (en) | Chimeric mesenchymal stem cell population and preparation method therefor, and method for producing parathyroid hormone using tonsil-derived stem cells | |
WO2015023147A1 (en) | Mtor/stat3 signal inhibitor-treated mesenchymal stem cell having immunomodulatory activity, and cell therapy composition comprising same, for preventing or treating immune disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12859499 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2012859499 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14367813 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014548657 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012354438 Country of ref document: AU Date of ref document: 20121218 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147020574 Country of ref document: KR Kind code of ref document: A |